BERKELEY, Calif.--(BUSINESS WIRE)--The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, today announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV).

加利福尼亚州伯克利市——（商业新闻短讯）——本公告的原始源语言文本是官方权威版本。翻译仅供参考，应与源语言文本交叉引用，源语言文本是唯一具有法律效力的文本版本。Insamo是一家率先发现膜渗透性和口服环肽的生物技术公司，今天宣布从Playfield Global，venBio和MRL Ventures Fund（MRLV）获得1200万美元的种子资本。

MRLV is a corporate venture arm of Merck & Co., Inc which invests in early-stage, preclinical therapeutics companies. As part of the financing, Matt Hershenson, co-founder, Playground Global, and Corey Goodman, Ph.D, co-founder, venBio, will join the company’s Board of Directors. Sahsen Ventures, BEVC, Civilization Ventures, and Axial Ventures also participated in the recent financing..

MRLV是默克公司（Merck＆Co.，Inc.）的企业风险投资子公司，该公司投资于早期临床前治疗公司。作为融资的一部分，Playway Global联合创始人马特·赫申森（Matt Hershenson）和venBio联合创始人科里·古德曼（Corey Goodman）博士将加入公司董事会。Sahsen Ventures、BEVC、文明风投和Axial Ventures也参与了最近的融资。。

Since its inception in 2022, CEO Timothy Craven, Ph.D., MBA, CSO Toby Passioura, Ph.D., and COO Glen Mcintyre, Ph.D. have been developing a platform to revolutionize drug discovery by combining ML-driven molecular design, ultra high-throughput molecular biology, and parallel synthetic chemistry to rapidly identify preclinical candidates that exhibit favorable pharmacological properties.

自2022年成立以来，首席执行官蒂莫西·克雷文（Timothy Craven）博士、工商管理硕士（MBA）、CSO托比·帕西奥拉（Toby Passioura）博士和首席运营官格伦·麦金太尔（Glen Mcintyre）博士一直在开发一个平台，通过结合ML驱动的分子设计、超高通量分子生物学和平行合成化学来彻底改变药物发现，以快速识别具有良好药理特性的临床前候选药物。

Their objectives encompass enhancing patient care by replacing injected or infused biologics with easily administered oral cyclic-peptide formulations as well as driving rapid drug discovery for currently intractable drug targets. Their 'turn-key' solution has the remarkable capability to consistently generate treatment candidates from scratch, regardless of prior knowledge about the disease target's structure, dynamics, or 'druggable' sites, and requires only a small vial of the target material..

他们的目标包括通过用易于给药的口服环肽制剂代替注射或输注的生物制剂来加强患者护理，以及推动目前难以治疗的药物靶标的快速药物发现。他们的“交钥匙”解决方案具有卓越的能力，可以从头开始持续产生候选治疗药物，而不必事先了解疾病靶标的结构，动力学或“可药物”位点，并且只需要一小瓶目标材料。。

'Insamo’s mission is to transform how we discover drugs for some of the most challenging diseases,' said Tim Craven, CEO and co-founder of Insamo. 'Macrocyclic peptides have been challenging to translate into the clinic. But we're changing that. Our innovative ML tools and screening technologies drive our ability to rapidly optimize drug efficacy.

Insamo首席执行官兼联合创始人蒂姆·克雷文（TimCraven）说，Insamo的使命是改变我们发现治疗某些最具挑战性疾病的药物的方式大环肽一直难以转化为临床。但我们正在改变这一点。我们创新的ML工具和筛选技术推动了我们快速优化药物功效的能力。

With our recent funding, we're poised to explore the full capabilities of these molecules and tackle breakthroughs in diseases once considered untreatable. Our platform's pioneering capability lies in its automated process of designing, synthesizing, and testing at an unprecedented scale. Our groundbreaking approach enables us to iterate our design cycle using trillions of proprietary experimental data points across an astronomical drug-like chemical space which we believe sets an entirely new standard for the application of scalable machine learning to drug design.'.

利用我们最近的资金，我们准备探索这些分子的全部功能，并解决一度被认为无法治疗的疾病的突破。我们平台的开创性能力在于其以前所未有的规模进行设计、合成和测试的自动化过程。我们开创性的方法使我们能够在天文药物样化学空间中使用数万亿专有实验数据点来迭代我们的设计周期，我们相信这为可扩展机器学习在药物设计中的应用设定了一个全新的标准。”。

'Insamo represents Playground's commitment to investing in companies that apply proprietary data for AI and machine learning in underexplored domains,” said Playground Global’s Matt Hershenson. “Through an AI and ML-driven drug discovery platform, Insamo is developing macrocycles using massively scaled in-house data.

游乐场环球公司的马特·赫森森（MattHershenson）表示：“Insamo代表着游乐场对在未充分开发的领域将专有数据应用于人工智能和机器学习的公司的投资承诺。”。“通过AI和ML驱动的药物发现平台，Insamo正在使用大规模的内部数据开发大环化合物。

Macrocycles are a natural and uniquely efficacious modality, and, powered by Insamo’s AI-driven engineering, they can create safer and more potent oral therapeutics. Insamo’s technology unlocks the potential to engineer macrocycles with improved properties and develop new therapies for previously undruggable targets across a broad range of diseases with high unmet need.”.

大环化合物是一种天然且独特有效的方式，并且在Insamo人工智能驱动的工程技术的支持下，它们可以创造更安全和更有效的口服疗法。Insamo的技术释放了设计具有改进性质的大环化合物的潜力，并为以前不可治疗的靶标开发了新的治疗方法，这些靶标涵盖了各种尚未满足需求的疾病。”。

“This innovative platform truly discovers membrane-permeable cyclic-peptides with oral bioavailability and binding capabilities akin to monoclonal antibodies,' said Dr. Corey Goodman, co-founder of venBio. 'The company's capacity to synthesize and screen libraries containing trillions of molecules facilitates the discovery of high-affinity ligands for drug targets across a spectrum of diseases.

venBio联合创始人科里·古德曼（CoreyGoodman）博士说：“这个创新平台真正发现了具有口服生物利用度和类似单克隆抗体结合能力的膜渗透性环肽。该公司合成和筛选含有数万亿分子的文库的能力有助于发现针对多种疾病的药物靶标的高亲和力配体。

Our investment in Insamo underscores our dedication to supporting companies pushing the boundaries of drug discovery to enhance patient outcomes.”.

我们对Insamo的投资强调了我们致力于支持推动药物发现边界的公司，以提高患者的治疗效果。”。

About Insamo

关于Insamo

Insamo is a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity. The founding team has deep scientific roots owing to time spent training in the frontier labs of David Baker at the University of Washington and Hiroaki Suga at the University of Tokyo.

Insamo是一家生物技术公司，率先发现具有抗体样结合亲和力的膜可渗透和口服环肽。由于在华盛顿大学DavidBaker和东京大学Hiroaki Suga的前沿实验室进行了大量训练，创始团队有着深厚的科学渊源。

Insamo has research sites in Berkeley, CA and Sydney, Australia. Insamo’s US headquarters is on campus at UC Berkeley’s Bakar Labs. For more information, visit www.insamo.com..

Insamo在加利福尼亚州伯克利和澳大利亚悉尼设有研究基地。Insamo的美国总部位于加州大学伯克利分校的巴卡尔实验室。有关更多信息，请访问www.insamo.com。。

About Playground Global

关于全球游乐场

Playground Global is an early-stage venture capital firm investing in deep tech and scientific founders who have developed breakthroughs in frontier technologies that will transform existing industries and create entirely new verticals. Learn more at playground.vc.

游乐场全球是一家早期风险投资公司，投资于深度科技和科学创始人，他们在前沿技术方面取得了突破，将改变现有行业，创造全新的垂直领域。在playfield.vc了解更多信息。

About venBio Partners

关于venBio Partners

venBio Partners is a life sciences investment firm that partners with industry leaders to build and invest in innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs. For more information, go to www.venbio.com.

venBio Partners是一家生命科学投资公司，与行业领导者合作建设和投资创新药物和技术，重点关注未满足医疗需求的新型疗法。有关更多信息，请访问www.venbio.com。

About MRL Ventures Fund

关于MRL风险投资基金

MRL Ventures Fund (MRLV) is a therapeutics-focused corporate venture fund of Merck & Co., Inc., Rahway, N.J., USA. From its headquarters in Cambridge, Mass., USA, the MRLV team invests globally in early-stage innovative therapeutics companies that are developing transformative medicines in any therapeutics area using any modality.

MRL Ventures Fund（MRLV）是美国新泽西州拉赫韦市默克公司（Merck＆Co.，Inc.）的一家专注于治疗的企业风险基金。MRLV团队从其位于美国马萨诸塞州剑桥的总部开始，在全球范围内投资于早期创新治疗公司，这些公司正在使用任何方式在任何治疗领域开发变革性药物。

The MRLV team of experienced-life sciences venture capital professionals is committed to supporting great entrepreneurs in their quest to create value through building companies that a meaningful impact on health and disease. For more information, visit www.mrlv.com..

MRLV团队由经验丰富的生命科学风险投资专业人员组成，致力于支持伟大的企业家通过建立对健康和疾病产生重大影响的公司来创造价值。有关更多信息，请访问www.mrlv.com。。